近两日,诺和诺德、礼来、信达生物,行业比较关注的减重药企纷纷公布最新业绩报告。其中意料之外又情理之中的事是:礼来替尔泊肽以365亿美元营收超越诺和诺德的361亿美元营收,成为全球“药王”。Zepbound(减重版替尔泊肽)全年收入135.42亿美元,增长175%;Wegovy(减重版司美格鲁肽)销售额为125.15亿美元,同比增长40%。单从减重产品营收来看,替尔泊肽也是超过司美格鲁肽的。值得关注...
Source Link近两日,诺和诺德、礼来、信达生物,行业比较关注的减重药企纷纷公布最新业绩报告。其中意料之外又情理之中的事是:礼来替尔泊肽以365亿美元营收超越诺和诺德的361亿美元营收,成为全球“药王”。Zepbound(减重版替尔泊肽)全年收入135.42亿美元,增长175%;Wegovy(减重版司美格鲁肽)销售额为125.15亿美元,同比增长40%。单从减重产品营收来看,替尔泊肽也是超过司美格鲁肽的。值得关注...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.